High-dose sodium stibogluconate treatment of cutaneous leishmaniasis in Kenya.
Cutaneous leishmaniasis caused by Leishmania aethiopica usually responds poorly to conventional doses of pentavalent antimonial drugs. We treated three patients with cutaneous leishmaniasis acquired in Kenya, presumed or documented to be caused by L. aethiopica, with intravenous sodium stibogluconate, 18 to 20 mg Sb/kg body-weight twice daily for 30 days. All patients had a good response to treatment, with disappearance of parasites from skin smears and cultures after 14 to 27 days, clinical healing of the lesions, and no recurrence during a three to 18-month follow-up. Side effects of treatment were minor. We conclude that this high dose sodium stibogluconate regimen is safe and effective for treating cutaneous leishmaniasis caused by L. aethiopica in Kenya.
D000293:Adolescent; D000328:Adult; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D005942:Gluconates / Q000627:therapeutic use*; D006801:Humans; D007630:Kenya; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male
D005942:Gluconates; D000967:Antimony Sodium Gluconate